PROMITIL Uses, Dosage, Side Effects and more
PROMITIL is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).
| Attribute | Details |
|---|---|
| Trade Name | PROMITIL |
| Generic | JNJ-27548547 |
| JNJ-27548547 Other Names | PROMITIL |
| Type | |
| Formula | C62H98N4O11S2 |
| Weight | Average: 1139.6 Monoisotopic: 1138.66735234 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Innovators Monograph
Search Medicines
